undamentalytics Newsletter
Sign in

Cytomx Therapeutics, Inc. income statement

In fiscal 2025, Cytomx Therapeutics, Inc. reported revenue of $76.2m, down 44.8% on the year before, operating income of −$22.4m (a -29.3% margin) and net income of −$17.4m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue158157260276837531011387618
Research and development112828559210413211311411278836973
General and administrative57132026343736394330303032
Operating income−15−30−33−60−46−78−141−81−116−101−625−22−87
Interest expense0022——————————
Income before tax−15−30−35−59−44−70−133−79−116−99332−17−79
Income tax000−0−114−0−14004000
Net income−15−30−35−59−43−85−133−65−116−99−132−17−80
Diluted EPS−$6.12−$8.81−$1.23−$1.63−$1.16————————−$0.44
Diluted shares (average)3m4m34m36m37m42m45m46m64m66m74m85m138m183m
EBITDA−14−29−32−58−45−76−139−78−113−99−427−21—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CTMX vs PRQRCELU vs CTMXCTMX vs SCYX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cytomx Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytomx Therapeutics, Inc.